September 30, 2015
FierceBiotech names Unum Therapeutics as one of its “Fierce 15” Biotech Companies of 2015
CAMBRIDGE, MA, September 30, 2015 – Unum Therapeutics today announced that it has been named by FierceBiotech as one of 2015’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Unum is a Cambridge, MA-based immunooncology company creating the next generation of engineered cellular therapies. The company has developed an antibody-coupled T-cell receptor (ACTR) that, when combined with tumor-specific antibodies, directs a patient’s T-cells to kill tumor cells. In contrast to other approaches, Unum’s cell therapy is not restricted to a specific antigen and may be useful for attacking a range of different types of cancers.
“We are honored to be recognized by FierceBiotech and to be included in such a strong, promising group of Fierce companies,” said Chuck Wilson, PhD, President & CEO of Unum Therapeutics. “In the past year, we have made significant progress in building our company and bringing our ACTR therapy to patients. We look forward to continuing to advance and expand our pipeline and to realizing the potential of our ACTR therapy in treating patients with hematological and solid tumors.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s thirteenth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at www.fiercebiotech.com/fierce15.
An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at www.fiercebiotech.com/signup.
About Unum Therapeutics
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, recently entered Phase 1 clinical testing to assess safety and efficacy. The company is headquartered in Cambridge, MA. For more information, visit http://www.unumrx.com